



Initiative- European Round Table Meetings

22. Informationstagung Tumordokumentation der klinischen und
epidemiologischen Krebsregister

Krebs – ein zunehmend gesellschaftliches Problem

- Die Zahl der Neuerkrankten wird in den nächsten zwei Dekaden in Europa von 3,6 auf 4,3 Millionen steigen, das bedeutet zusätzlich 716 000 jährlich.
- Die Zahl der Patienten, die mit Krebs leben, steigt entsprechend steiler an - Krebs wird die chronische Erkrankung Nummer 1.
- Global sterben 23 000 Patienten pro Tag an Krebs.
- Zu Zeit sind Gesundheitsversorgung, Prävention und Forschung nicht in der Lage, dieses Problem auszutarieren.

Gesundheitsausgaben rund um Krebs in der EU

- €35.7 Milliarden in 1995
- €83.2 Milliarden in 2014

Drugs:

- €7.6 Milliarden in 2005
- €19.1 Milliarden in 2014

B. Jönsson

9/10 drugs are failing registration
Costs for one approved drug
800 million USD





Comprehensive Cancer Care Netzwerke in Deutschland

Deutschland

- Bevölkerung: 81 Millionen
- Föderaler Staat mit 16 Bundesländern





Onkologen im niedergelassenen Bereich

Ca. 620 Onkologen

Ca. 320 onkologische Urologen

Ca. 140 onkologische Gynaekologen





Krebsversorgung in Europa

Inhalte National Cancer Control Plans:

- Registrierung
- Öffentliche Gesundheitskommunikation
- Prävention
- Früherkennung
- Integrative Krebsversorgung
- Quality of Care
- Krebsforschung




Krebsversorgung in Europa

Vorhandene Unterschiede in den verschiedenen Europäischen Ländern

- Cancer-Burden
- Struktur
- Strategie
- Versorgung/ Resources

Improving Cancer Care in Europe- 1st ERTM, Germany



1. ERTM, Germany, 2014

Improving Cancer Care in Europe -
Share best practice and learn which institutional structures
are beneficial and why?

- 1.) Which **structures** are necessary on a national level to be able to define and develop a **strategic approach** to **quality** in cancer care?
- 2.) Which **criteria** are necessary / important to **implement the defined strategy** for cancer care?
- 3.) What is necessary to **measure quality cancer** care in your system?

2. *ERTM, Germany, 2015*

Improving structural development in oncology – transformation of theoretical health care standards and knowledge into a practical approach

- 1.) Which **strategies of communication** between clinical cancer registries and cancer centres are needed to improve **quality** of care?
- 2.) Which **procedures and communication networks** are essential in **cancer centers** to guarantee optimal **interdisciplinary, multi-professional** patient care?
- 3.) What is necessary to include the **patient perspective** into **structural development** of cancer care networks?

3. *ERTM, Germany, 2016*

Current developments in cancer care: including the patient perspective

- 1.) How much **transparency** is needed in patient care, how can it be implemented?
- 2.) How does the cancer care system **react** on **gain of knowledge**, how **fast** can standardized reactions be implemented on basis of patient needs?
- 3.) How does a **benchmark for decision making** in partnership with the patient need to be defined?

4. *ERTM, Germany, 2017*

Quality control and improvement of cancer care – what is needed

- 1.) How does the **data flow** need to be described?
- 2.) How do **communication processes** between institutions need to be described?
- 3.) How does **result-communication** need to be described?

Dutch Cancer Society

Mission:


- Reduce cancer rates as soon as possible, and get it under control. We are here to help people living with cancer and those who share their lives.

Goal:

- Less cancer, more cure and a better quality of life for cancer patients



Cancer survival in The Netherlands compared to other European countries

5-year age-standardised relative survival for adult patients with cancer, diagnosed 2000–2007



Source: EUROCARE-5 Lancet Oncology 2013, and report 'Kankerzorg in Beeld', IKNL

Cancer in Iceland

-  Over 50% of cancers are diagnosed after the age of 65 years.
-  Cancer causes 28% of all deaths in Iceland.
- One of three Icelanders.....



Infrastructure primary care

- Public health care system with primary health care centers geographically distributed and with local responsibilities.



The Swedish approach

- Regional coordinated cancer centres were established at six geographic areas 1974 - the oncologic university clinics got the mission to coordinate the cancer care
- Regional clinical guidelines with referral recommendations were implemented
- Clinical cancer registries were linked to the regional cancer registries – population based clinical registries
- Regional cancer registries report to the central Swedish Cancer Registry
- University clinics and academic institutions were under a single leadership

A successful development

- At that time, no economic problems – all could agree, no competition
- Clinical guidelines for multidisciplinary cancer care were developed for main tumour diseases
- Adherence to clinical guidelines was assessed
- Recommended referral pathways were respected
- Psychooncology was implemented
- Early detection recommendations were disseminated
- Clinical trials activity was structured in several geographic areas
- Epidemiological research expanded

Spanish NHS Cancer Strategy

Decision of the *Consejo Interterritorial of NHS* 2006:

- Updated in 2010 and this year (2105), a new cancer strategy for the next four years is under discussion
- Scientific Board with advisors from scientific societies, patient groups and representatives of all **regions**
- **From prevention to palliative care:** Aims essentially to coordinate the activities of **regions** and to promote cancer plans in the regions that at the time may not have one
- Based on the experience of the regional cancer plans: Catalonia (2001), Andalusia (2004), Valencia (2005), Castilla-Leon (2005)

Spanish NHS Cancer Strategy

- Consensus based approach to the **objectives and targets** in Cancer Strategy among all stakeholders (regions, Ministry, scientific societies and patient groups)
- **Evidence** as input to policy making but not the only matter:
 - Policy discussions about **budgetary** impact
 - **Values at stake** different according to region and scientific societies.
 - **Equity of access** as the central issue for policy discussion, but focused on access to new drugs
 - **Centres of reference at national level** with specific budget for these procedures at central level, but eliminated three years ago: **problems of referral of patients**
 - **Regionalised strategies for centralising specific procedures limited to one region**, but others with interest. Innovation role of some regions worthy of mention

Based on inventory of Eurocourse:

160 'certified' cancer registries (CRs) in Europe

General cancer registries: N=140 (15-20% national, 75-80% regional)

- **All sites** → dozens of studies of:
 - Incidence by subsite & subtype (ICD-O 3)
 - Survival, often with stage at diagnosis
- Good assessment of multiple tumours
- Sampling frames for in-depth work
- Linked to many other cohorts
 - Including cohorts of radiotherapy patients



Specialised cancer registries (tumor, tract or age) national/regional


- About 20 isolated
 - Many more, part of a general CR registry
 - Also called: clinical CR
 - About 10 childhood CRs
 - Often with (too !!) much unused clinical data
 - useful support to clinical oncology
 - especially elderly, side effects
- (Siesling et al, 2015)

Take home messages for the registry aspect


- Develop **programmatic research platform** for CRs
 - Get energy from MSc and PhD students
- **Multi-regional projects** of dedicated registries
 - Within and across country borders
 - Study question-based minimal data on processes and outcomes
- Develop **early 'success'**: lightfooted through the swamps
- **Step by step**: big adventures are vulnerable
- Make it possible that **others can join** the bandwagon
- **Educate** your program owner (constantly)

Publications:





Translational cancer research – a coherent research continuum





Vielen Dank

Dr. Ulrike Helbig MBA
Deutsche Krebsgesellschaft
Kuno-Fischer Str. 8
14057 Berlin
helbig@krebsgesellschaft.de
www.krebsgesellschaft.de